Workshop：Progress and Advances in Preclinical immuno-Oncology Research
The rise of cancer immunotherapy such as immune checkpoint modulators, bispecific antibodies, T cell therapy and personalized cancer vaccines instigated a wide range of unique preclinical and translational challenges. The demand for preclinical models and approaches to minimize translational failures in immuno-oncology is at an all-time high. The need for leveraging phenotypic features of models, for rational design of combination therapies, and for researching the cancer-immune cell interactions add to the complexity of translational research in immune-oncology. SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Final Agenda
1:00-4:35pm BJT
December 17, 2020
Bibo hall, Parkyard Hotel
699 Bibo Road, Zhang Jiang High Tech Park Pudong, Shanghai
Time |
Topic |
Speaker(s) and Affiliation |
1:00–1:30 pm |
Registration |
|
1:30–1:40 pm |
Opening speech |
|
1:40-2:20 pm |
Exploration and Development of Next Generation Tumor Immunotherapy Antibody |
Wenzhi Tian, MD, Chairman & CEO of ImmuneOnco Biopharma Co., Ltd |
2:20-3:00 pm |
Animal modeling for immuno-oncology drug discovery |
Davy Ouyang, Vice President of Scientific Research & Innovation at Crown Bioscience Inc |
3:00-3:15 pm |
Coffee break |
|
3:15-3:55 pm |
Immuno-Oncology Therapies & Humanized Animal Models |
Jia Zeng, R & D Project Leader of ALLCELLS |
3:55-4:35 pm |
Genetically engineered mouse models in oncology research and cancer medicine |
Haiyan Zhu, Director of Industrial Customer Department at Shanghai Model Organisms Center, Inc. |
你也可能感兴趣
Cre-ERT2在无Tamoxifen诱导的情况下，在细胞质内处于无活性状态；当Tamoxifen诱导后，Tamoxifen的代谢产物4-OHT（雌激素类似物）与ERT结合，可使Cre-ERT2进核发挥Cre重组酶活性。
查看
